X.T.L. Biopharmaceuticals Partners with NCCS to Revolutionize CAR-T Cancer Treatment in Singapore

Innovative CAR-T Therapy Partnership Aims to Transform Cancer Treatment in Singapore

Elpis Biopharmaceuticals, a clinical-stage cell therapy company based in Lexington, Massachusetts, forges a strategic partnership with the National Cancer Centre Singapore (NCCS) to advance its armored CAR-T technologies. This collaboration, formalized through a Memorandum of Understanding (MOU) signed on July 27, 2025, seeks to transition Elpis's clinically validated therapies into first-in-human trials targeting a range of solid tumors, including colorectal, pancreatic, and ovarian cancers. Currently, CAR-T cell therapy has limited approval for specific blood cancers; this partnership represents a pivotal move to broaden its applications to solid tumors, potentially revolutionizing treatment options for patients suffering from these aggressive forms of cancer.

Elpis Biopharmaceuticals commits to providing its cutting-edge technologies, which include multi-mechanism armor, bispecific targeting antibodies, and cytokine cocktails. These innovations are already being tested in ongoing global clinical trials, specifically EPC-002 and EPC-003. The collaboration with NCCS will establish a dedicated laboratory space, where Elpis will integrate its advanced equipment, thereby enhancing research capabilities and operational efficiency within the Singaporean healthcare landscape. Dr. Yan Chen, the Founder and CEO of Elpis, underscores the significance of this partnership, stating, "This partnership reflects our commitment to rapidly advancing innovative immunotherapies," highlighting the company’s dedication to expediting the translation of groundbreaking therapies from discovery to clinical application.

The partnership also leverages NCCS's expertise in clinical research and robust trial infrastructure, which will be invaluable in evaluating the novel cell therapy candidates developed by Elpis. By combining their resources and expertise, both organizations aim to facilitate a streamlined process for bringing these advanced treatments to patients in Singapore and beyond. This initiative marks a significant milestone in the journey of transforming advanced cell therapies from laboratory research to bedside applications, with the potential to deliver effective and life-saving cancer treatments to a broader patient population.

In other relevant developments, Elpis Biopharmaceuticals continues to reinforce its position in the biopharmaceutical sector by focusing on the innovative aspects of its technology. The collaboration with NCCS not only enhances its research capabilities but also positions the company as a key player in the evolution of cancer therapies in Asia. The partnership reflects a growing trend in the industry where cross-border collaborations are increasingly viewed as essential to accelerate the development of new treatments and improve patient outcomes globally.